Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapy

Background: Despite advances in the treatment of metastatic castration-resistant prostate cancer (mCRPC), primary and secondary resistance to current therapies remains. Elevated circulating sphingolipids are associated with poor outcomes in patients with mCRPC, including therapeutic resistance and s...

Descripción completa

Detalles Bibliográficos

Autores principales:	Rhiannon Mellor, Luke Ardolino, Tahlia Scheinberg, Michael Fitzpatrick, Hui-Ming Lin, Paul Bonnitcha, David Sullivan, Peter J. Meikle, Martin R. Stockler, Tania Moujaber, Anthony Joshua, Lisa Horvath
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	SAGE Publishing 2024-12-01
Colección:	Therapeutic Advances in Medical Oncology
Acceso en línea:	https://doi.org/10.1177/17588359241307814
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!